• Irradiate feeder cell lines for development of Chimeric Antigen Receptor T (CAR-T) cell lines.• Monitor, order, receive reagents and consumables, organize inventory.• Write and implement exposure control and safety SOPs, train new employees.• Routine mycoplasma testing.• Perform installation, cleaning, maintenance, repair, sterilization, and decontamination of equipment, or schedule same by vendors.o Including installation of plumbing of CO2 tanks and vacuum systems for BSCs.• Schedule and monitor laboratory Regulated Medical Waste (RMW) disposal

• Screened >200 new CRISPR-associated (Cas) molecules for genetic editing capabilities.o Performed and improved high-throughput cell culture assays on proprietary cell lines for evaluation of editing activity & specificity by NGS• Tested spacer/Cas combinations for editing capability via AAV deliveryo ROSA26 Safe harbor locuso CNS-associated target genes

Organize day-to-day laboratory operations.Assist and design CRISPR genetic modification experiments.o Ordered supplies and organized inventory, including plasmid and cell bankso Set up supply alternatives in response to supply chain difficultieso Implemented safety plans and trained new employeeso Performed routine endotoxin and mycoplasma testingo Scheduled maintenance, repair, sterilization, and decontamination of equipmento Laboratory and Regulated Medical Waste disposalo Assisted with and trained new employees and direct reports to generate lab reagentso Assisted in vivo operations as neededo Conducted safety training and employee orientationo Interface with: o construction contractors for opening of initial and expansion buildings, o EH&S inspectors as needed, o I.T. staff to install temperature monitoring systems and maintain network security.

• Evaluating IL-2 mutein candidates for treatment of auto-immune diseases. This is a continuation of my role with Celgene.

• Evaluating IL-2 mutein candidates for treatment of auto-immune diseases.

• Evaluating drug candidates for treatment of biochemical symptoms associated with Alzhemier’s disease

• Develop mouse models as candidates for investigation of small molecule therapeutics in treatment of age-related diseases.• Evaluate senescence-related phenotypes for markers of senescence.• Establish relationships between senescence and age-related diseases.

• Developed a potential diagnostic non-isotopic in situ hybridization (ISH) assay • For use in treatment of non-small cell lung carcinaomas using immune checkpoint blockade therpaies.• Developed multiplex reporter platform for use with Formalin-Fixed Paraffin-Embedded tissue sections.• Chromogenic and Fluorescent In-Situ Hybridization• Chromogenic Immuno-Histo-Chemistry and Immunofluorescence• Dako Autostainer, Ventana Benchmark and Discovery autostainers, Leica Autostainer XL, and manual assays.

• Created and optimized oligonucleotide probe panels for cDNA-based sequence-specific multiplex genotyping assays. • Authored and conducted stability studies of new products.• Wrote Verification and Validation test plans and reports for C1qScreen assay reagents, LABScreen antibody detection assays, LABType genotyping assays, and LABScan 3D flow cytometer (product launched November 2013). • Supervised projects in accordance with Design Control procedures for Class I and Class II medical devices

• Characterized interactions between the PI3K-Akt-PTEN signalling pathway and the E2A transcription factor gene products.• Characterized effects of post-translational modifications of E2A gene products.• Examined cell-autonomous nature of PTEN-deficient lymphomas & acute myeloid leukemias.

• Developed lentiviral RNAi vectors directed against the PML tumor-suppressor gene product, to investigate the role of PML in cellular senescence.

• Developed Adeno-Associated Virus libraries as gene therapy vectors for use in treatment of neuro-degenerative diseases.